About: Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients with COVID-19
Creator	Haines, David Williamson, Brian Abbas, Amr Bradley, Christopher Dmitrienko, Alex Gaines, Rick O'connell, Thomas Rusia, Akash Schott, Jason Tawney, Adam
Source	Elsevier; PMC
abstract	ABSTRACT Background Hydroxychloroquine and azithromycin (HCQ/AZM) are being widely used to treat COVID-19 despite the known risk of QT interval prolongation and unknown risk of arrhythmogenesis in this population. Objective The study aimed to characterize corrected QT (QTc) prolongation in a cohort of hospitalized COVID-19 patients treated with combination HCQ/AZM. Methods A retrospective cohort of COVID-19 hospitalized patients treated with HCQ/AZM was reviewed. The QTc interval was calculated prior to drug administration and for the first 5 days following initiation. The primary end point was the magnitude of QTc prolongation, and factors associated with QTc prolongation. Secondary endpoints were incidences of sustained ventricular tachycardia or ventricular fibrillation and all-cause mortality. Results Among 415 patients receiving concomitant HCQ/AZM, the mean QTc increased from 443±25 msec to a maximum of 473±40 msec (87 (21%) had a QTc ≥500 msec). Factors associated with QTc prolongation ≥500 msec were age (p < 0.001), body mass index <30 kg/m2 (p = 0.005), heart failure (p < 0.001), elevated creatinine (p = 0.005), and peak troponin (p < 0.001). The change in QTc was not associated with death over the short period of the study in a population where mortality was already high (hazard ratio, 0.998, p = 0.607). No primary high-grade ventricular arrhythmias were observed. Conclusions An increase in QTc was seen in hospitalized COVID-19 patients treated with HCQ/AZM. Several clinical factors were associated with greater QTc prolongation. Changes in QTc were not associated with increased risk of death.
has issue date	2020-08-05(xsd:dateTime)
bibo:doi	10.1016/j.jacep.2020.07.016
has license	els-covid
sha1sum (hex)	aee2bbee40a510721d88114d2e9121301a4bb91b
schema:url	https://doi.org/10.1016/j.jacep.2020.07.016
resource representing a document's title	Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients with COVID-19
has PubMed Central identifier	PMC7406234
schema:publication	JACC Clin Electrophysiol
resource representing a document's body	covid:aee2bbee40a510721d88114d2e9121301a4bb91b#body_text
is schema:about of	named entity 'risk' named entity 'msec' named entity 'primary' named entity 'peak' named entity 'factors' named entity 'creatinine' named entity 'msec' named entity 'The' named entity 'population' named entity 'mortality' named entity 'Patients' named entity 'Therapy' named entity 'USED' named entity 'VENTRICULAR ARRHYTHMIAS' named entity 'RESPONSE TO' named entity 'INCREASED' named entity 'MEAN' named entity 'OBJECTIVE' named entity 'HOSPITALIZED PATIENTS' named entity 'PRE' named entity 'prior' named entity 'endpoints' named entity 'COVID-19' named entity 'treated' named entity 'high' named entity 'hospitalized' named entity 'QTc prolongation' named entity 'greater' named entity 'arrhythmias' named entity 'magnitude' named entity 'Hydroxychloroquine' named entity 'patients' named entity 'age' named entity 'prolongation' named entity 'retrospective cohort' named entity 'The change' named entity 'adverse' named entity 'QTc interval' named entity 'receiving' named entity 'QT interval prolongation' named entity 'risk of death' named entity 'end point' named entity '21%' named entity 'msec' named entity 'msec' named entity 'QT prolongation' named entity 'COVID-19' named entity 'ECG' named entity 'msec' named entity 'msec' named entity 'corrected QT interval' named entity 'hydroxychloroquine' named entity 'QTc' named entity 'QTc' named entity 'COVID-19' named entity 'QTc' named entity 'QTc prolongation' named entity 'COVID-19' named entity 'troponin' named entity 'corrected QT' named entity 'QTc prolongation' named entity 'arrhythmias' named entity 'hazard ratio' named entity 'Hydroxychloroquine' named entity 'elevated' named entity 'ventricular fibrillation' named entity 'QTc prolongation' named entity 'infection' named entity 'QTc' named entity 'QTc' named entity 'QTc' named entity 'hydroxychloroquine' named entity 'health care' named entity 'torsade de pointes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software